PRKN and hepatocellular carcinoma: For example, parkin, which has been shown to have a promoting effect in tumors such as HCC [84,85], drives apoptosis in HCC cells by inhibiting the NF-κB pathway by promoting the degradation of TRAF2 and TRAF6 [84,86].